BioDetego is developing the next generation of cancer diagnostics. Supported by clinical data in multiple cancer types, our diagnostic platform, VASPfore, determines a person’s risk of developing metastasis and need for chemotherapy.

VASPfore will empower people to make treatment decisions based upon individual need for chemotherapy – reducing the undertreatment of people who need chemotherapy and the harmful overtreatment of people who don’t.